目的 观察ABD活性因子对肺癌患者化疗后骨髓抑制情况的影响。 方法 选取44例接受化疗的肺癌患者，随机分为干预组、对照组，22例干预组患者口服ABD活性因子，22例治疗背景相同的对照组患者作常规化疗，比较两组患者骨髓抑制情况的差异。结果 43例患者按计划完成化疗，对照组1例患者因重度骨髓抑制终止化疗。干预组骨髓抑制情况显著改善（P<0.05）。与对照组比较，干预组Ⅲ~Ⅳ级骨髓抑制率显著降低（P<0.05），且白细胞、中性粒细胞、血小板抑制情况显著改善（P<0.05，P<0.05，P<0.05）。与对照组比较，干预组（非小细胞肺癌：紫杉醇+顺铂，培美曲塞+顺铂）化疗药物导致的骨髓抑制情况明显改善（P<0.05，P<0.05，P<0.05，P<0.05）。结论 ABD活性因子可改善肺癌患者化疗后骨髓抑制情况，尤其降低Ⅲ~Ⅳ级骨髓抑制发生率，提升白细胞、中性粒细胞、血小板水平，同时降低铂类、紫杉醇类、抗代谢类化疗药物毒副作用。
1罗敏
,
2吴晓军
,
2张欣
,
3董光
,
4熊骊龙
,
4王鹏程
,
1高葵
,
1余萍
,
1何美
,
5杜驰
,
5蒋鸥
,
6石汉平
. ABD活性因子对肺癌患者化疗后骨髓抑制的作用研究[J]. 肿瘤代谢与营养电子杂志, 2019
, 6(3)
: 346
-350
.
DOI: 10.16689/j.cnki.cn11-9349/r.2019.03.015
Objective To explore the effect of ABD bioactives on myelosuppression alleviation in lung cancer patients during chemotherapy. Methods 44 lung cancer patients who received chemotherapy were randomly divided into intervention group and control group. 22 lung patients in intervention group received ABD Bioactives for adjuvant therapy. 22 lung cancer patients were treated conventionally. The difference of myelosuppression was compared between the two groups. Results 43 patients completed chemotherapy as planned， and 1 patients of the control group terminated chemotherapy due to severe myelosuppression. Myelosuppression of intervention group was significantly alleviated (P<0.05). The incidence of myelosuppression of Ⅲ~Ⅳ was significantly lower (P<0.05)， and the inhibition of leukocytes， granulocytes and platelets was significantly alleviated (P<0.05，P<0.05，P<0.05) compared with the control group. The myelosuppression induced by paclitaxel +platinum-based agents， pemetrexed+ platinum-based agents was significantly alleviated (P<0.05，P<0.05，P<0.05，P<0.05) compared with the control group. Conclusion ABD Bioactives can alleviate chemotherapy-induced myelosuppression in lung cancer patients， especially reduce the incidence of Myelosuppression of Ⅲ~Ⅳ， increase the levels of leukocytes， granulocytes and platelets， reduce the toxicity and side effects of platinum-based agents， paclitaxel， antimetabolite.
1.Shiv KS，Ambuj K， Aarati S， et al. Incidence and attributes of chemotherapy induced myelotoxicity， anemia and neutropenia in adults with cancer in Nepal: a cross-sectional observational study. J Oncol Pharm Pract. 2018;［Epub ahead of print］.
2.Bhm K， Weber D， Lang K， et al. Palliative radiotherapy for leptomeningeal carcinomatosis-analysis of outcome， prognostic factors， and symptom response. Front Oncol. 2019;8:641.
3.Bosly A， Bron D， Hoof AV，et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87(4):277-283.
4.Chirivella I， Bermejo B， Insa A， et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat.2009;114(3):479-484.
5.Pettengell R， Johnson HE， Lugtenburg PJ， et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 2012;20(3):647-652.
6.Camera E， Picardo M. Analytical methods to investigate glutathione and related compounds in biological and pathological process. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781(1-2):181-206.
7.Balendiran GK， Dabur R， Fraser D. The role of glutathione in cancer. Cell Biochem Funct. 2004;22:343-352.
8.Gamcsik MP， Kasibhatla MS， Teeter SD， Colvin OM. Glutathione levels in human tumors. Biomarkers. 2012;17(8):671-691.
9.Baruchel S， Viau G. In vitro selective modulation of cellular glutathione by a humanized native milk protein isolate in normal cells and rat mammary carcinoma model. Anticancer Res. 1996;16(3A):1095-1099.
10.Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000;20(6C):4785-4792.
11.Gutman J， The Role of intensive glutathioen therapy in chemotherapy and radiotherapy for cancer patients. Nutri Oncology. 2016;11(15):1.
12.Meisel H. Food-derived bioactive proteins and peptides as potential components of nutraceuticals.Curr Pharm Design. 2007;13(9):873-874.
13.杨睿悦，裴新荣，张绍峰，等. 海洋蛋白肽及其与灵芝多糖配伍的防辐射作用实验研究. 食品与发酵工业. 2008;34(5):1-5.
14.World Health Organization. WHO handbook for reporting. Results of Cancer Treatment， Geneva， Switzerland:World Health Organis-ation. 1979.
15.Han W， Yu Y， Xin YL. Local signals in stem cell-based bone marrow regeneration. Cell Res.2006;16(2):189-195.
16.许红霞， 林欣， 王佳佳， 等. 重庆市某医院常见恶性肿瘤住院患者营养状况调查. 肿瘤代谢与营养电子杂志. 2017;4(1):45-50.
17.Baracos VE. Cancer-associated malnutrition. Eur J Clin Nutr. 2018;72(9):1255-1259.
18.Haugen BR， Alexander EK， Bible KC， et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.
19.Heskethp J， Arena F， Patel D， et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004;100(4):859-868.
20.Dy G， Adjei A. Understanding， Recognizing， and managing toxicities of targeted anticancer therapies. Ca Cancer J. Clin. 2013;63(4):249-279.
21.李德爱， 王大志，张书瑜， 等. 抗肿瘤药物与化疗患者发生骨髓抑制情况的药物流行病学研究. 中国药学杂志. 2010;45(24):1968-1970.
22.Lu H， Zhu S， Qian L， et al. Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapyinduced bone marrow suppression and lethal toxicity. Blood. 2012;119(21):4868-4877.
23.韦润莲， 杨玉芳， 钟小斌， 等. 应用含顺铂方案治疗鼻咽癌患者致骨髓抑制的调查分析.中国药房.2011;22(36):3392-3394.
24.Heuer L，Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrin. 2005;16(4):287-290.
25.Tecza K， Lanuszewska J， Butkiewicz D， et al. Pharmacogenetics of toxicity of 5-fluorouracil， doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018;9(10):9114-9136.
26.Akard L， Kantarjian HM， Nicolini FE， et al. Incidence and management of myelosuppression in patients with chronic-and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leuk Lymphoma. 2016;57(3):654-665.
27.Collins TA， Hattersley MM， Yates JWT， et al. Translational modeling of drug-induced myelosuppression and effect of pretreatment myelosuppression for AZD5153， a selective BRD4 Inhibitor. CPT Pharmacometrics Syst Pharmacol. 2017;6(6):357-364.
28.Tozer RG， Tai P， Falconer W，Ducruet T， Karabadjian A， Bounous G， Molson JH， Drge W. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid Redox Signal 2008;10:395-402.
29.Raghunathan VK， Ellis EM，Justice NAT， et al. Involvement of reduced glutathione and glutathione reductase in the chronic toxicity of hexavalent chromium to monocytes in vitro. Toxicology. 2007;231(2-3):105-106.
30.Regan RF， Guo YP. Potentiation of excitotoxic injury by high concentrations of extracellular reduced glutathione. Neuroscience.1999;91(2):463-470.
31.Mattia GD，Bravi MC， Laurenti O， et al. Influence of reduced glutathione infusion on glucose metabolism in patients with non-insulin-dependence diabetes mellitus. Metabolism. 1998;147(8):993-997.
32.Ponsoda X， Bort R， Jover R， et al. Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. Biochem Pharmacol. 1999;58(10):1579-1585.
